CFTR and cystic fibrosis: Previous studies have indicated that SAHA also acts as a proteostasis-modulator that may help restore the membrane expression and function of misfolded ΔF508-CFTR [3, 17, 34], warranting its further preclinical evaluation for treating chronic CF-lung disease.